Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways

Area of Science:

• Genomics
• Computational Biology
• Cancer Research

Background:

• Distinguishing functional cancer driver genes from passenger mutations is clinically significant but challenging.
• Current methods rely heavily on existing knowledge of oncogenic effects and clinical trial data.
• Clinical sequencing generates vast genomic data, offering opportunities for novel computational discovery.

Purpose of the Study:

• To develop and validate a computational method (MAGPIE) for identifying driver genes and mutations within cancer pathways.
• To leverage mutual exclusivity patterns in genomic data to probabilistically nominate functional candidates.
• To expand the potential patient population for targeted cancer therapies.

Main Methods:

• Proposed a statistical and computational likelihood approach (MAGPIE).
• Modeled passenger mutation rates in relation to tumor mutational burden.
• Utilized mutual exclusivity patterns within oncogenic pathways to identify drivers.
• Validated using simulations and applied to primary melanoma and Cancer Genome Atlas data.

Main Results:

• MAGPIE accurately identified known driver genes in the RTK-RAS pathway in melanoma.
• The method nominated several rare variants as potential drivers requiring functional validation.
• Comprehensive evaluation demonstrated MAGPIE's performance against existing tools.

Conclusions:

• MAGPIE offers a robust computational approach for identifying cancer driver genes and mutations.
• This method can uncover novel driver candidates beyond current knowledge bases.
• Enables broader application of genetically targeted therapies by identifying new targets.